TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

Richard L. Kradin; David S. Lazarus; Steven M. Dubinett; Julie Gifford; Beverly Grove; James T. Kurnick; Frederic I. Preffer; Clare E. Pinto; Elise Davidson; Ronald J. Callahan; H. William Strauss

doi:10.1016/S0140-6736(89)91609-7

TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

Richard L. Kradin, David S. Lazarus, Steven M. Dubinett, Julie Gifford, Beverly Grove, James T. Kurnick, Frederic I. Preffer, Clare E. Pinto, Elise Davidson, Ronald J. Callahan, H. William Strauss

Research output: Contribution to journal › Article › peer-review

314 Scopus citations

Abstract

Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 10¹⁰) and continuous infusions of recombinant human interleukin-2 (1-3 x 10⁶ U/m² per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.

Original language	English
Pages (from-to)	577-580
Number of pages	4
Journal	The Lancet
Volume	333
Issue number	8638
DOIs	https://doi.org/10.1016/S0140-6736(89)91609-7
State	Published - 18 Mar 1989
Externally published	Yes

Access to Document

10.1016/S0140-6736(89)91609-7

Cite this

@article{c51e8c7238f54755ad0123ac05aea1a3,

title = "TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER",

abstract = "Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 1010) and continuous infusions of recombinant human interleukin-2 (1-3 x 106 U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.",

author = "Kradin, {Richard L.} and Lazarus, {David S.} and Dubinett, {Steven M.} and Julie Gifford and Beverly Grove and Kurnick, {James T.} and Preffer, {Frederic I.} and Pinto, {Clare E.} and Elise Davidson and Callahan, {Ronald J.} and Strauss, {H. William}",

note = "Funding Information: This study was supported by grants from the National Institutes of Health (CA43244, CA44324) and Ortho Pharmaceutical Corporation.",

year = "1989",

month = mar,

day = "18",

doi = "10.1016/S0140-6736(89)91609-7",

language = "English",

volume = "333",

pages = "577--580",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8638",

}

TY - JOUR

T1 - TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

AU - Kradin, Richard L.

AU - Lazarus, David S.

AU - Dubinett, Steven M.

AU - Gifford, Julie

AU - Grove, Beverly

AU - Kurnick, James T.

AU - Preffer, Frederic I.

AU - Pinto, Clare E.

AU - Davidson, Elise

AU - Callahan, Ronald J.

AU - Strauss, H. William

N1 - Funding Information: This study was supported by grants from the National Institutes of Health (CA43244, CA44324) and Ortho Pharmaceutical Corporation.

PY - 1989/3/18

Y1 - 1989/3/18

N2 - Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 1010) and continuous infusions of recombinant human interleukin-2 (1-3 x 106 U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.

AB - Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 1010) and continuous infusions of recombinant human interleukin-2 (1-3 x 106 U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0024510298&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(89)91609-7

DO - 10.1016/S0140-6736(89)91609-7

M3 - Article

C2 - 2564111

AN - SCOPUS:0024510298

SN - 0140-6736

VL - 333

SP - 577

EP - 580

JO - The Lancet

JF - The Lancet

IS - 8638

ER -

TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

Abstract

Access to Document

Fingerprint

Cite this